News
LENZ
4.110
+0.24%
0.010
Weekly Report: what happened at LENZ last week (1102-1106)?
Weekly Report · 2d ago
LENZ Therapeutics Price Target Cut to $9.00/Share From $10.00 by Citigroup
Dow Jones · 6d ago
LENZ Therapeutics Is Maintained at Buy by Citigroup
Dow Jones · 6d ago
Citigroup Maintains Buy on LENZ Therapeutics, Lowers Price Target to $9
Benzinga · 6d ago
LENZ Therapeutics (LENZ) Receives a Buy from Citi
TipRanks · 6d ago
Lenz Therapeutics price target lowered to $9 from $10 at Citi
TipRanks · 6d ago
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 11/03 17:05
LENZ (LENZ) Q3 2026 Earnings Call Transcript
NASDAQ · 11/02 19:17
Weekly Report: what happened at LENZ last week (1026-1030)?
Weekly Report · 11/02 10:11
Bank of America Securities Remains a Hold on LENZ Therapeutics (LENZ)
TipRanks · 10/30 16:55
LENZ Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 10/30 11:50
LENZ Therapeutics Price Target Cut to $16.00/Share From $38.00 by HC Wainwright & Co.
Dow Jones · 10/30 11:50
HC Wainwright & Co. Maintains Buy on LENZ Therapeutics, Lowers Price Target to $16
Benzinga · 10/30 11:40
Lenz Therapeutics price target lowered to $16 from $38 at H.C. Wainwright
TipRanks · 10/30 10:16
LENZ Therapeutics (LENZ) Stock Rallies As Q3 Results Deepen Loss Concerns
Simply Wall St · 10/29 22:32
Russell 2000 estimated to drop 83 stocks in December rebalance - Stephens
Seeking Alpha · 10/29 19:44
LENZ Therapeutics Price Target Cut to $45.00/Share From $50.00 by TD Cowen
Dow Jones · 10/29 17:35
LENZ Therapeutics Is Maintained at Buy by TD Cowen
Dow Jones · 10/29 17:35
TD Cowen Maintains Buy on LENZ Therapeutics, Lowers Price Target to $45
Benzinga · 10/29 17:25
LENZ Therapeutics Q3 2026 Earnings Call Transcript
Benzinga · 10/29 13:24
More
Webull provides a variety of real-time LENZ stock news. You can receive the latest news about LENZ THERAPEUTICS INC through multiple platforms. This information may help you make smarter investment decisions.
About LENZ
LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.